Aardvark enters $150M equity distribution agreement with Piper Sandler

Aardvark Therapeutics, Inc.

May sell up to $150M of common stock at market through Piper Sandler as agent.
Commission of 3.0% of gross sales price per share sold under agreement.
Company has no obligation to sell any shares; sales at Company's discretion.
Agreement filed as Exhibit 10.1; shelf registration on Form S-3 filed same day.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aardvark Therapeutics, Inc. entered into Equity Distribution Agreement with Piper Sandler & Co. valued at up to $150,000,000 (effective 2026-03-23).

Action: entry
Agreement: atm program
Counterparty: Piper Sandler & Co.
Value: up to $150,000,000
Effective: 2026-03-23

Exact text from the filing

On March 23, 2026, Aardvark Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co., as sales agent (the “Agent”), pursuant to which the Company may, from time to time, in its sole discretion, offer and sell through or to the Agent, shares (“Shares”) of its common stock, par value $0.00001 per share.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Aardvark Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-120164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.